POLYGON Therapeutics and PARCC Collaborate to Establish Early R&D Unit for Cardiovascular Disease Innovation
Therapeutics and PARCC Collaborate
to Establish Early R&D Unit for Cardiovascular Disease Innovation
Paris, France, June 30th, 2023 – POLYGON Therapeutics, a biotechnology company, is thrilled to announce the establishment of an early Research and Development (R&D) unit in partnership with the Paris Cardiovascular Research Center (PARCC). POLYGON Therapeutics was created from the work of Prof. Hafid-Ait-Oufella, who heads Team 5 “Immuno-metabolic mechanisms of cardiovascular diseases” in this research center. This collaboration brings together the expertise of both organizations to accelerate the development of innovative therapies that address unmet medical needs in the field of cardiovascular health.
The newly established early R&D unit, located within the PARCC research center, will serve as a hub for POLYGON’s cutting-edge scientific research and discovery efforts. By leveraging PARCC’s renowned infrastructure, resources, and collaborative environment, POLYGON aims to enhance its capabilities in cardiovascular disease research and accelerate the translation of scientific discoveries into potential breakthrough therapies.
“We are delighted to join forces with
PARCC, a distinguished leading research center in cardiovascular diseases, to
establish our early R&D unit”, said Mohamed ABOU ALI, Chief Executive
Officer at POLYGON Therapeutics. “This collaboration represents a
significant step forward in our mission to revolutionize cardiovascular disease
treatments and improve patient outcomes.”
Prof. Hafid AIT-OUFELLA, Chief Scientific Officer at POLYGON Therapeutics added “It is very exciting to see the potential clinical application of our experimental research come to fruition.”
The PARCC research center, a globally recognized institution dedicated to cardiovascular disease research, will provide POLYGON with access to state-of-the-art laboratories, cutting-edge technologies, and a network of renowned cardiovascular researchers and clinicians. This partnership will foster collaboration and knowledge sharing, driving innovation and the development of novel therapeutic approaches.
Chantal Boulanger, Director of PARCC, expressed enthusiasm about the collaboration: “We are excited to welcome POLYGON Therapeutics into our research center. This partnership aligns with our mission to bridge the gap between basic science and clinical applications, and together, we can make significant strides in the field of cardiovascular disease research.”
POLYGON Therapeutics’ early R&D unit will focus on the discovery and development of groundbreaking treatments for a range of cardiovascular diseases, including post-ischemic heart failure, atherosclerosis, and other immune related conditions. The company’s innovative approach combines advanced technologies, such as biotherapies, precision medicine, and targeted cytotoxic immunity, to develop therapies that are more effective, personalized, and ultimately capable of improving patient outcomes.
This collaboration between POLYGON Therapeutics and PARCC signifies a mutual commitment to advancing cardiovascular research and translating scientific discoveries into transformative treatments. By combining their respective strengths, expertise, and resources, both organizations aim to revolutionize the field of cardiovascular medicine and address the critical healthcare challenges faced by millions of patients worldwide.
About POLYGON Therapeutics:
POLYGON Therapeutics is a French biotech company developing innovative drugs to treat patients suffering from cardiovascular diseases and acute immune disorders. Its main drug is a first-in-class monoclonal antibody, PLG-101.
Cardiovascular Diseases (CVDs) are the number 1 cause of death globally: in recent times, 18 million people have died annually from CVDs, representing 31% of all global deaths. Among these deaths, 85% are due to heart attacks and strokes. Despite a better management of risk factors (e.g. hypercholesterolemia and hypertension) and significant progress in CVD care, new therapeutic approaches remain untapped.
POLYGON’s first therapeutic solution, PLG-101, aims to target a specific immune response happening during myocardial infarction to enhance post-ischemic cardiac remodeling. It has already shown successful results on preclinical models. Potential in other cardiovascular indications has been highlighted.
About PARCC INSERM:
The Paris Cardiovascular Research Center (PARCC) is a world renowned research center specialized in cardiovascular diseases. PARCC’s mission is to advance scientific knowledge, bridge the gap between basic science and clinical applications, and develop innovative therapies to combat cardiovascular disorders.
For media inquiries, please contact:
Contact POLYGON Therapeutics : Tatiana Monseur – email@example.com
Contact PARCC Inserm: Kevin Boye – firstname.lastname@example.org